KDNY | Chinook Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	40.30 - 40.51
52 Week Range	18.34 - 40.51
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	3,281,100
Average Volume	2,044,466
Shares Outstanding	67,049,499
Market Cap	2,708,129,265
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-10-06

Valuation
Profitability
Growth
Health
P/E Ratio	-12.47
Forward P/E Ratio	N/A
EPS	-3.24
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	214
Country	USA
Website	KDNY

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

KDNY's peers: ASND, CDMO, TSVT, VRCA

*Chart delayed

Analyzing fundamentals for KDNY we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see KDNY Fundamentals page.

Watching at KDNY technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on KDNY Technicals page.